CCEL Stock Overview
Engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 1/6 |
Cryo-Cell International, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.87 |
| 52 Week High | US$9.50 |
| 52 Week Low | US$4.19 |
| Beta | 0.51 |
| 11 Month Change | 26.53% |
| 3 Month Change | 15.55% |
| 1 Year Change | 87.83% |
| 33 Year Change | -36.15% |
| 5 Year Change | n/a |
| Change since IPO | -4.61% |
Recent News & Updates
Shareholder Returns
| CCEL | US Healthcare | US Market | |
|---|---|---|---|
| 7D | -14.2% | -4.6% | -1.2% |
| 1Y | 87.8% | 1.1% | 30.4% |
Return vs Industry: CCEL exceeded the US Healthcare industry which returned 1.1% over the past year.
Return vs Market: CCEL exceeded the US Market which returned 30.4% over the past year.
Price Volatility
| CCEL volatility | |
|---|---|
| CCEL Average Weekly Movement | 10.9% |
| Healthcare Industry Average Movement | 7.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CCEL's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CCEL's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 85 | David Portnoy | www.cryo-cell.com |
Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, auto-immune diseases, multiple sclerosis, Alzheimer’s disease, Parkinson’s diseases. The company manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells.
Cryo-Cell International, Inc. Fundamentals Summary
| CCEL fundamental statistics | |
|---|---|
| Market cap | US$64.82m |
| Earnings (TTM) | -US$8.93m |
| Revenue (TTM) | US$31.84m |
2.0x
P/S Ratio-7.1x
P/E RatioIs CCEL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CCEL income statement (TTM) | |
|---|---|
| Revenue | US$31.84m |
| Cost of Revenue | US$12.12m |
| Gross Profit | US$19.71m |
| Other Expenses | US$28.64m |
| Earnings | -US$8.93m |
Last Reported Earnings
Aug 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.11 |
| Gross Margin | 61.92% |
| Net Profit Margin | -28.04% |
| Debt/Equity Ratio | -112.2% |
How did CCEL perform over the long term?
See historical performance and comparisonDividends
3.2%
Current Dividend Yieldn/a
Payout RatioDoes CCEL pay a reliable dividends?
See CCEL dividend history and benchmarks| Cryo-Cell International dividend dates | |
|---|---|
| Ex Dividend Date | Nov 15 2024 |
| Dividend Pay Date | Nov 29 2024 |
| Days until Ex dividend | 6 days |
| Days until Dividend pay date | 8 days |
Does CCEL pay a reliable dividends?
See CCEL dividend history and benchmarks